68Ga-Prostate-Specific Membrane Antigen Positron Imaging Reveals Intense Uptake in Chronic Rhinitis: A Previously Unreported Finding

Introduction

To date, radionuclide-labeled ligands targeting prostate-specific membrane antigen (PSMA) have shown great potential for both the diagnostic and therapeutic aspects of advanced prostate cancer [Al-Ibraheem et al. Semin Nucl Med 2024. DOI: 10.1053/j.semnuclmed.2024.02.003. Online ahead of print]. The mechanism of action of this imaging technique involves the use of radiolabeled ligands that target PSMA, a glycoprotein found on prostate cancer cells [Koschel et al. Curr Opin Urol 2019; 29: 569–577]. PSMA positron emission tomography (PET) imaging has shown greater sensitivity and specificity compared to traditional methods like computed tomography (CT) scans and skeletal scintigraphy [Hofman et al. Lancet 2020; 395: 1208–1216]. However, PSMA expression is not limited to prostate cancer and can also be present in other benign and malignant conditions, leading to potential misdiagnoses [Voter et al. Semin Nucl Med 2023; 54: 119–131]. False positive results have been increasingly reported with the growing availability of PSMA agents worldwide [Voter et al. Semin Nucl Med 2023; 54: 119–131].

Publication History

Received: 08 June 2024

Accepted after revision: 07 October 2024

Article published online:
20 November 2024